Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This s...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1871296 |
| _version_ | 1797677238586441728 |
|---|---|
| author | Francesco Paolo Bianchi Simona Mascipinto Pasquale Stefanizzi Sara De Nitto Cinzia Germinario Silvio Tafuri |
| author_facet | Francesco Paolo Bianchi Simona Mascipinto Pasquale Stefanizzi Sara De Nitto Cinzia Germinario Silvio Tafuri |
| author_sort | Francesco Paolo Bianchi |
| collection | DOAJ |
| description | The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster. |
| first_indexed | 2024-03-11T22:42:10Z |
| format | Article |
| id | doaj.art-c79e402f5c1849c592392f578d56e91c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:10Z |
| publishDate | 2021-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-c79e402f5c1849c592392f578d56e91c2023-09-22T08:51:53ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-07-011772078208410.1080/21645515.2020.18712961871296Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort studyFrancesco Paolo Bianchi0Simona Mascipinto1Pasquale Stefanizzi2Sara De Nitto3Cinzia Germinario4Silvio Tafuri5Aldo Moro University of BariAldo Moro University of BariAldo Moro University of BariAldo Moro University of BariAldo Moro University of BariAldo Moro University of BariThe persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster.http://dx.doi.org/10.1080/21645515.2020.1871296long time immunogenicitymeasles elimination eranatural boosteradditional boosterhealthcare workers |
| spellingShingle | Francesco Paolo Bianchi Simona Mascipinto Pasquale Stefanizzi Sara De Nitto Cinzia Germinario Silvio Tafuri Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study Human Vaccines & Immunotherapeutics long time immunogenicity measles elimination era natural booster additional booster healthcare workers |
| title | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
| title_full | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
| title_fullStr | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
| title_full_unstemmed | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
| title_short | Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study |
| title_sort | long term immunogenicity after measles vaccine vs wild infection an italian retrospective cohort study |
| topic | long time immunogenicity measles elimination era natural booster additional booster healthcare workers |
| url | http://dx.doi.org/10.1080/21645515.2020.1871296 |
| work_keys_str_mv | AT francescopaolobianchi longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT simonamascipinto longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT pasqualestefanizzi longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT saradenitto longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT cinziagerminario longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy AT silviotafuri longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy |